본문으로 건너뛰기
← 뒤로

Life-threatening dapagliflozin-associated euglycaemic diabetic ketoacidosis in a postoperative patient.

BMJ case reports 2025 Vol.18(1) 🌐 cited 1 Diabetes and associated disorders
TL;DR This case is of a woman with type 2 diabetes and hypertension in her 50s who underwent an incarcerated umbilical hernia repair and abdominoplasty and was readmitted with nausea, vomiting, loss of appetite, low-grade fever and breathing difficulty two days after discharge.
OpenAlex 토픽 · Diabetes and associated disorders Diabetes Treatment and Management Pancreatic function and diabetes

Mukaddam SH, Tooblani HM, Gupta R

관련 도메인

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Sajid Hasanali Mukaddam, Hasan Mohammed Tooblani, Riya Gupta (2025). Life-threatening dapagliflozin-associated euglycaemic diabetic ketoacidosis in a postoperative patient.. BMJ case reports, 18(1). https://doi.org/10.1136/bcr-2024-260473
MLA Sajid Hasanali Mukaddam, et al.. "Life-threatening dapagliflozin-associated euglycaemic diabetic ketoacidosis in a postoperative patient.." BMJ case reports, vol. 18, no. 1, 2025.
PMID 39773969

Abstract

Euglyceamic diabetic ketoacidosis (EuDKA) is an uncommon but serious diabetes mellitus complication associated with risk factors such as fasting, surgery, pregnancy and, more recently, the use of sodium-glucose cotransporter-2 inhibitors (SGLT2i). This case is of a woman with type 2 diabetes and hypertension in her 50s who underwent an incarcerated umbilical hernia repair and abdominoplasty. Two days after discharge, she was readmitted with nausea, vomiting, loss of appetite, low-grade fever and breathing difficulty. Preoperatively, her diabetes management included an SGLT2i. She was diagnosed with EuDKA with high anion gap metabolic acidosis, a medical emergency similar to diabetic ketoacidosis. The normal blood glucose levels in EuDKA can mask the condition, which poses a conundrum for physicians in the emergency department/intensive care units as it may delay diagnosis and treatment, worsening the outcomes. To mitigate this risk, SGLT2i should be stopped 3-4 days before planned surgery with appropriate adjustments to the insulin regimen.

추출된 의학 개체 (NER)

유형영어 표현한국어 / 풀이UMLS CUI출처등장
시술 abdominoplasty 복부성형술 dict 1
해부 blood glucose scispacy 1
약물 glucose C0017725
glucose
scispacy 1
질환 euglycaemic diabetic ketoacidosis scispacy 1
질환 diabetic ketoacidosis C0011880
Diabetic Ketoacidosis
scispacy 1
질환 diabetes mellitus C0011849
Diabetes Mellitus
scispacy 1
질환 diabetes C0011847
Diabetes
scispacy 1
질환 hypertension C0020538
Hypertensive disease
scispacy 1
질환 umbilical hernia C0019322
Umbilical hernia
scispacy 1
질환 nausea, vomiting scispacy 1
질환 fever C0015967
Fever
scispacy 1
질환 metabolic acidosis C0220981
Metabolic acidosis
scispacy 1
질환 low-grade scispacy 1
기타 sodium-glucose cotransporter-2 scispacy 1
기타 SGLT2i → sodium-glucose cotransporter-2 inhibitors scispacy 1
기타 insulin scispacy 1

MeSH Terms

Humans; Diabetic Ketoacidosis; Female; Diabetes Mellitus, Type 2; Benzhydryl Compounds; Glucosides; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Postoperative Complications; Abdominoplasty; Herniorrhaphy

🔗 함께 등장하는 도메인

이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들

관련 논문